The global targeted sequencing and resequencing market accounted for USD 6.49 billion in 2023 and is expected to reach at USD 63.13 billion by 2034 with a CAGR of 22.97% during the forecast period 2024-2034. The market will grow due to advancements in Next-Generation Sequencing (NGS) technologies, the growing need for pharmacogenomics and personalized medicine, government initiatives and funding support, collaborations and partnerships, and research and development activities in genomics.
Targeted sequencing makes it possible to identify genetic variants that affect drug efficacy and response, which can be used to design individualized treatment plans. The increasing focus on pharmacogenomics and customized medicine drives the market for targeted sequencing and resequencing technologies. For instance, in March 2024, Qiagen and Berry Genomics partnered to provide a combined NGS solution for targeted sequencing in non-invasive prenatal testing.
By type, the DNA-based targeted sequencing segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the growing demand for personalized medicine, advancements in NGS technologies, and increased focus on precision diagnostics and pharmacogenomics. For instance, in April 2024, Agilent Technologies introduced the SureSelectXT HS Target Enrichment Kit for targeted DNA sequencing in clinical research applications. Additionally, the RNA-based targeted sequencing segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising interest in transcriptomic research, expanding applications in gene expression analysis, and the growing importance of RNA-based biomarkers in disease diagnosis and therapeutic development.
By technology, the sequencing segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the increased adoption of whole genome sequencing (WGS) and whole exome sequencing (WES) for comprehensive genetic analysis, clinical diagnostics, and research applications. For instance, in February 2024, Thermo Fisher Scientific introduced the Ion Torrent Genexus System+, a tabletop NGS technology designed for targeted sequencing applications. Additionally, the resequencing segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding demand for population-scale genomic studies, advancements in bioinformatics tools, and increasing applications in evolutionary biology and biodiversity conservation.
By application, the clinical segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the growing adoption of targeted sequencing for disease diagnosis, treatment selection, and monitoring, alongside increasing integration into clinical workflows and guidelines. For instance, BGI Group introduced the BGISEQ-500 sequencer in January 2024, a high-throughput machine developed exclusively for focused sequencing processes. Additionally, the drug development segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising emphasis on precision medicine approaches, increasing use of targeted sequencing in drug discovery and development processes, and growing interest in identifying genetic biomarkers for drug response and adverse reactions.
By end-user, the academic research segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the expansion of genomic research initiatives, growing collaborations between academia and industry, and increasing funding support for academic research projects in genomics and related fields. For instance, Roche Diagnostics received FDA approval for their AVENIO ctDNA Assay for cancer recurrence surveillance based on targeted sequencing in March 2024. Additionally, the hospitals and clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for genomic testing services, integration of sequencing technologies into clinical practice, and increasing adoption of precision medicine approaches in healthcare delivery.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of key market players, advanced healthcare infrastructure, and substantial investments in genomic research and precision medicine initiatives. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing adoption of NGS technologies, and rising investments in genomics research and precision medicine initiatives across the region. For instance, in February 2024, PerkinElmer acquired NGS business BioNano Genomics, boosting its portfolio for structural variation research using targeted sequencing techniques.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Targeted sequencing makes it possible to identify genetic variants that affect drug efficacy and response, which can be used to design individualized treatment plans. The increasing focus on pharmacogenomics and customized medicine drives the market for targeted sequencing and resequencing technologies. For instance, in March 2024, Qiagen and Berry Genomics partnered to provide a combined NGS solution for targeted sequencing in non-invasive prenatal testing.
By type, the DNA-based targeted sequencing segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the growing demand for personalized medicine, advancements in NGS technologies, and increased focus on precision diagnostics and pharmacogenomics. For instance, in April 2024, Agilent Technologies introduced the SureSelectXT HS Target Enrichment Kit for targeted DNA sequencing in clinical research applications. Additionally, the RNA-based targeted sequencing segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising interest in transcriptomic research, expanding applications in gene expression analysis, and the growing importance of RNA-based biomarkers in disease diagnosis and therapeutic development.
By technology, the sequencing segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the increased adoption of whole genome sequencing (WGS) and whole exome sequencing (WES) for comprehensive genetic analysis, clinical diagnostics, and research applications. For instance, in February 2024, Thermo Fisher Scientific introduced the Ion Torrent Genexus System+, a tabletop NGS technology designed for targeted sequencing applications. Additionally, the resequencing segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding demand for population-scale genomic studies, advancements in bioinformatics tools, and increasing applications in evolutionary biology and biodiversity conservation.
By application, the clinical segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the growing adoption of targeted sequencing for disease diagnosis, treatment selection, and monitoring, alongside increasing integration into clinical workflows and guidelines. For instance, BGI Group introduced the BGISEQ-500 sequencer in January 2024, a high-throughput machine developed exclusively for focused sequencing processes. Additionally, the drug development segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising emphasis on precision medicine approaches, increasing use of targeted sequencing in drug discovery and development processes, and growing interest in identifying genetic biomarkers for drug response and adverse reactions.
By end-user, the academic research segment accounted for the highest revenue-grossing segment in the global targeted sequencing and resequencing market in 2023 owing to the expansion of genomic research initiatives, growing collaborations between academia and industry, and increasing funding support for academic research projects in genomics and related fields. For instance, Roche Diagnostics received FDA approval for their AVENIO ctDNA Assay for cancer recurrence surveillance based on targeted sequencing in March 2024. Additionally, the hospitals and clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for genomic testing services, integration of sequencing technologies into clinical practice, and increasing adoption of precision medicine approaches in healthcare delivery.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of key market players, advanced healthcare infrastructure, and substantial investments in genomic research and precision medicine initiatives. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing adoption of NGS technologies, and rising investments in genomics research and precision medicine initiatives across the region. For instance, in February 2024, PerkinElmer acquired NGS business BioNano Genomics, boosting its portfolio for structural variation research using targeted sequencing techniques.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Technology, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Targeted Sequencing And Resequencing Market Report 2023 - 2034
Targeted Sequencing And Resequencing Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- DNA-based targeted sequencing
- RNA-based targeted sequencing
Targeted Sequencing And Resequencing Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Sequencing
- Re-sequencing
Targeted Sequencing And Resequencing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Clinical application
- Plant and animal sciences
- Drug development
- Others
Targeted Sequencing And Resequencing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals and clinics
- Academic research
- Others
Targeted Sequencing And Resequencing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Targeted Sequencing And Resequencing Market: Type Estimates & Trend Analysis
8. Targeted Sequencing And Resequencing Market: Technology Estimates & Trend Analysis
9. Targeted Sequencing And Resequencing Market: Application Estimates & Trend Analysis
10. Targeted Sequencing And Resequencing Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Targeted Sequencing And Resequencing Market
13. Europe Global Targeted Sequencing And Resequencing Market
14. Asia Pacific Global Targeted Sequencing And Resequencing Market
15. Latin America Global Targeted Sequencing And Resequencing Market
16. MEA Global Targeted Sequencing And Resequencing Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Qiagen N.V.
- Agilent Technologies Inc.
- BGI Group
- Roche Diagnostics
- Pacific Biosciences of California Inc.
- Oxford Nanopore Technologies Ltd.
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- Genewiz
- Eurofins Scientific
- Macrogen Inc.
- ArcherDX
- Novogene Corporation.
